Affinity Asset Advisors, LLC
Position in TSHA — Taysha Gene Therapies, Inc.
CIK 1773195
NEW YORK, NY
Position in TSHA
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$4,470,000
-$13,680,000 QoQ
Shares Held
1,000,000
-69.7% QoQ
Ownership
0.348%
of shares outstanding
% of Portfolio
0.27%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in TSHA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Affinity Asset Advisors, LLC holds $1,518,254,571 across 81 Biotechnology names. TSHA ranks #56 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
1,284,926 | $108,152,221 | |
| 2 | XENE |
Xenon Pharmaceuticals Inc.
|
1,675,000 | $97,401,250 | |
| 3 | ERAS |
Erasca, Inc.
|
5,350,000 | $86,563,000 | |
| 4 | INSM |
INSMED Inc
|
480,000 | $78,489,600 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
2,800,000 | $77,560,000 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
1,279,134 | $64,519,518 | |
| 7 | CNTA |
Centessa Pharmaceuticals plc
|
1,400,000 | $55,608,000 | |
| 8 | PRAX |
Praxis Precision Medicines, Inc.
|
170,000 | $54,772,300 |
All Filings in TSHA
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,470,000 | 1,000,000 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $18,150,000 | 3,300,000 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $9,810,000 | 3,000,000 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $462,000 | 200,000 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||